TPB
Turning Point Brands, Inc.110.86
+1.25+1.14%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Manufacturing ramp, ALP launch details
Q&A drilled into Modern Oral execution, confirming U.S. production lines qualify soon to supplement Indian supply, easing constraints and teasing year-end margin gains via freight tweaks. ALP's Q2 bricks-and-mortar push should echo FRE's early ramp, with lumpy high-ROI sales investments ahead. Management waved off innovation needs, touting current flavors, and saw taxes as a level field. FRE and ALP both hit expectations despite Q4 tariffs denting gross margins. Distribution white space remains vast. Brands win long-term.
Key Stats
Market Cap
2.11BP/E (TTM)
34.22Basic EPS (TTM)
3.24Dividend Yield
0%Recent Filings
10-K
FY2025 results
Turning Point Brands crushed FY2025 with net sales jumping 28% to $463M, fueled by Stoker's segment exploding 69% on modern oral pouches while Zig-Zag dipped 7% amid tariff hits and strategic shifts. Q4 momentum roared in Stoker's, where modern oral growth accelerated y/y, lifting margins to 59% despite sales ramp costs; Zig-Zag held steady but squeezed by imports. Operating income rose 18% to $95M, backed by $223M cash and no ABL draws. Share repurchases paused, dividends held firm. FDA enforcement shifts threaten quarterly product access.
8-K
Modern Oral sales explode 266%
Turning Point Brands reported Q4 2025 net sales up 29.2% to $121.0 million, driven by Modern Oral's 266% surge to $41.3 million—now 34% of total—while Zig-Zag fell 12.8%. Adjusted EBITDA rose 14% to $30.0 million. Modern Oral dominates growth. FY2026 guides $220-$240 million gross revenue, but FDA PMTA costs persist.
10-Q
Q3 FY2025 results
Turning Point Brands posted Q3 net sales of $119M, up 31% y/y, fueled by Stoker's segment surging 81% to $75M on modern oral strength while Zig-Zag dipped 11% to $44M. Operating income climbed 24% y/y to $26M with gross margins expanding to 59%, yet SG&A rose on shipping and joint venture costs. Diluted EPS hit $1.13, up 66% y/y, confirmed against 18.7M shares. Cash swelled to $201M on $33M OCF less $10M capex (FCF $23M derived), bolstered by $98M ATM equity raise; swapped $250M 5.625% 2026 Notes for $300M 7.625% 2032 Notes due Mar 2032, with $67M ABL availability. CDS divested Jan 2025 for 49% GWO stake. FDA enforcement priorities loom large.
8-K
Expands ATM offering by $200M
Turning Point Brands nearly maxed out its $100M at-the-market equity offering, selling $99,999,137 in common stock via B. Riley and Barclays since December 13, 2024. It amended the prospectus on November 5, 2025, adding $200M capacity. Fresh runway for capital. Sales agents may continue banking ties.
8-K
Q3 sales soar 31%
IPO
Employees
Sector
Industry
BTI
British American Tobacco Indus
57.29-0.45
CHUC
Charlie's Holdings, Inc.
0.18+0.01
ISPR
Ispire Technology Inc.
2.82+0.09
KAVL
Kaival Brands Innovations Group
0.18+0.02
MO
Altria Group, Inc.
59.33+0.24
NBND
NetBrands Corp.
0.00-0.00
PM
Philip Morris International Inc
157.95-0.46
TLRY
Tilray Brands, Inc.
13.94+3.01
TOBAF
TAAT Global Alternatives Inc.
0.04+0.00
VPRB
VPR Brands, LP
0.02+0.00